Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma.

The document titled "Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma" presents the findings of two phase 3 trials that investigated the use of zolbetuximab, an IgGl monoclonal antibody, in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma. The results showed that when combined with first-line chemotherapy, zolbetuximab led to significantly longer progression-free survival and overall survival compared to placebo plus chemotherapy. This treatment was particularly effective for patients with HER2-negative tumors that were positive for claudin 18.2. The study provides valuable information for clinicians and researchers in the field of gastric cancer treatment. [Extracted from the article]